LEMMA HEALTH

Eczema Treatments

Age
Eczema Severity Level
Max Side Effects Tolerated
Insurance Coverage
Preferred Types of Treatments
Include Steroidal Creams
Investigational
  • Treatment:
    Olumiant (Baricitinib)
    Experimental
    Effectiveness:
    Who is this for?:
    If you need strong and fast relieve and treatments applied to the skin are not sufficient or appropriate
    If your child is over 2 years old, needs strong and fast relieve, and treatments applied to the skin are not sufficient or appropriate
    Side Effects:
    Cost:
    -
    Delivery:
    Oral once daily
    Studies
Over-the-counter medicine
  • Treatment:
    Ceramides and Magnesium Cream (Cer-Mg)
    Effectiveness:
    Who is this for?:
    If you are looking for a moisturizing cream without steroids
    If you are looking for a moisturizing cream without steroids
    Side Effects:
    Cost:
    -
    Delivery:
    Topical daily
    Studies
  • Treatment:
    Hydrocortisone (Topical Corticosteroid)
    Effectiveness:
    Who is this for?:
    For temporary relief of itch and rashes
    For temporary relief of itch and rashes
    Side Effects:
    Cost:
    -
    Delivery:
    Topical 1-4 daily
    Studies
Procedure
  • Treatment:
    Phototherapy (UV-A, Narrowband UV-B)
    Effectiveness:
    Who is this for?:
    If you wish to avoid or reduce reliance on topical and drug treatments
    If your child wishes to avoid or reduce reliance on topical and drug treatments
    Side Effects:
    Cost:
    -
    Delivery:
    Light exposure 2-3 times per week
    Studies
  • Treatment:
    Bleach baths (Sodium hypochlorite)
    Effectiveness:
    Who is this for?:
    Add-on to other treatments if you experience frequent skin infections
    Add-on to other treatments if you experience frequent skin infections
    Side Effects:
    Cost:
    -
    Delivery:
    Procedure weekly
    Studies
  • Treatment:
    Allergen-specific immunotherapy (AIT)
    Effectiveness:
    Who is this for?:
    If your AD is related to allergies and other treatment-options are exhausted
    If your AD is related to allergies and other treatment-options are exhausted
    Side Effects:
    Cost:
    -
    Delivery:
    Injection weekly
    Studies
Prescription
  • Treatment:
    Rinvoq (Upadacitinib)
    Effectiveness:
    Who is this for?:
    If you need rapid and strong relief of itch and other treatments have failed
    If your child is 12+ years, needs rapid and strong relief of itch and other treatments have failed
    Side Effects:
    Cost:
    -
    Delivery:
    Oral once daily
    Studies

    Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial.

    (Full Study)
    Summary:
    The oral medication upadacitinib showed significant improvement in eczema severity compared to placebo, with higher doses showing better results and an acceptable safety profile.
    Study Type
    Randomized Controlled Trial
    Studied Population
    167 adults with moderate-to-severe atopic dermatitis with inadequate control by topical treatment
    Results
    EASI % improvement: Significant improvement for all doses vs placebo (p=0.03 for 7.5mg, p<0.001 for 15mg and 30mg)

    Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

    (Full Study)
    Summary:
    Upadacitinib taken once daily as a pill significantly improved eczema symptoms compared to placebo, with 70% of patients on the 15mg dose and 80% on the 30mg dose showing major improvement in their eczema after 16 weeks.
    Study Type
    Randomized Controlled Trial
    Studied Population
    847 adolescents (12-17 years) and adults (18-75 years) with moderate-to-severe atopic dermatitis
    Results
    EASI-75: +53.3%
    vIGA-AD response: +39.8%

    Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

    (Full Study)
    Summary:
    Upadacitinib (oral medication) worked better and faster than dupilumab (injection) in treating moderate-to-severe eczema, with 72.4% vs 62.6% of patients achieving significant skin improvement at 16 weeks.
    Study Type
    Randomized Controlled Trial
    Studied Population
    673 adults with moderate-to-severe atopic dermatitis
    Results

    Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

    (Full Study)
    Summary:
    Upadacitinib (an oral medication) combined with topical steroids was significantly more effective than placebo plus topical steroids in treating moderate-to-severe eczema, with 65-77% of patients showing major improvement compared to 26% on placebo.
    Study Type
    Randomized Controlled Trial
    Studied Population
    901 adults (18-75 years) and adolescents (12-17 years) with moderate-to-severe atopic dermatitis
    Results
    EASI-75: +38.1%
    vIGA-AD: +28.5%

    Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

    (Full Study)
    Summary:
    Upadacitinib treatment showed lasting effectiveness through 52 weeks in treating moderate-to-severe atopic dermatitis, with both 15mg and 30mg doses maintaining improvements in skin clearance and itch relief, though the 30mg dose showed slightly better results with some increased side effects.
    Study Type
    Randomized Controlled Trial
    Studied Population
    1609 adults and adolescents aged 12-75 years with moderate-to-severe atopic dermatitis
    Results
    EASI-75: 56.0
    vIGA-AD 0/1: 48.2
    WP-NRS: 52.3

    Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results.

    (Full Study)
    Summary:
    Upadacitinib combined with topical steroids was effective and safe for treating moderate-to-severe eczema over a 52-week period, with higher doses showing better improvement in symptoms.
    Study Type
    Randomized Controlled Trial
    Studied Population
    901 patients aged 12-75 years with chronic moderate-to-severe atopic dermatitis
    Results

    Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

    (Full Study)
    Summary:
    This long-term safety study of upadacitinib across multiple inflammatory conditions showed the medication was generally well-tolerated, with different side effect patterns observed depending on the underlying condition being treated.
    Study Type
    Observational
    Studied Population
    6991 patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
    Results

    JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications

    (Full Study)
    Summary:
    When comparing different medications, JAK inhibitors were found to have a higher risk of cancer than TNF inhibitors, but showed no difference in cancer risk compared to placebo or methotrexate. Overall, cancer was a rare occurrence across all treatments.
    Study Type
    Review
    Studied Population
    adults with rheumatoid arthritis, psoriatic arthritis, psoriasis, axial spondyloarthritis, inflammatory bowel disease or atopic dermatitis
    Results
    JAKi vs Placebo IRR: 0.71
    JAKi vs Methotrexate IRR: 0.77
    JAKi vs TNFi IRR: 1.5
  • Treatment:
    Cibinqo (Abrocitinib)
    Effectiveness:
    Who is this for?:
    If you need rapid relief of itch and other symptoms
    If your child is 12+ years and needs rapid relief of itch and other symptoms
    Side Effects:
    Cost:
    -
    Delivery:
    Oral once daily
    Studies

    Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

    (Full Study)
    Summary:
    Once-daily oral abrocitinib (200mg or 100mg) significantly improved eczema symptoms compared to placebo in adolescents and adults with moderate-to-severe atopic dermatitis, with improvements seen as early as 2 weeks into treatment.
    Study Type
    Randomized Controlled Trial
    Studied Population
    391 patients 12 years or older with moderate-to-severe atopic dermatitis
    Results
    IGA response: 28.7
    EASI-75: 50.5
    PP-NRS response: 43.8

    Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

    (Full Study)
    Summary:
    Both doses of oral abrocitinib (100mg and 200mg daily) were more effective than placebo in treating moderate-to-severe eczema, with the 200mg dose showing faster itch relief than dupilumab, though both treatments had similar overall effectiveness at 16 weeks.
    Study Type
    Randomized Controlled Trial
    Studied Population
    838 patients with moderate-to-severe atopic dermatitis unresponsive to topical agents or warranting systemic therapy
    Results

    Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

    (Full Study)
    Summary:
    The oral medication abrocitinib taken once daily was effective in treating moderate-to-severe eczema in both teens and adults, with higher doses showing better results than lower doses.
    Study Type
    Randomized Controlled Trial
    Studied Population
    387 adolescents and adults (≥12 years) with moderate-to-severe atopic dermatitis
    Results
    IGA response: 36% improvement vs placebo
    EASI-75: 51% improvement vs placebo

    Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

    (Full Study)
    Summary:
    Abrocitinib, a daily oral medication, showed manageable safety for long-term use in treating moderate-to-severe eczema, though some side effects like nausea, headache, and infections were observed at different rates depending on the dose.
    Study Type
    Review
    Studied Population
    2856 patients with moderate-to-severe atopic dermatitis
    Results

    Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate to severe atopic dermatitis: results from the JADE REGIMEN phase 3 trial.

    (Full Study)
    Summary:
    The study found that continuous treatment with abrocitinib helped prevent disease flares in patients who initially responded to treatment, and if flares occurred, restarting treatment was effective in regaining control of symptoms.
    Study Type
    Randomized Controlled Trial
    Studied Population
    1233 patients with moderate-to-severe atopic dermatitis
    Results
    Response regain after flare (IGA 0/1): {'200mg': 36.6, '100mg': 58.8, 'placebo': 81.6}
    Response regain after flare (EASI): {'200mg': 55.0, '100mg': 74.5, 'placebo': 91.8}

    Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND).

    (Full Study)
    Summary:
    Abrocitinib was effective in treating moderate-to-severe eczema in patients who had previously used dupilumab, regardless of whether they had responded well to dupilumab or not. The medication showed good results in improving both skin symptoms and itch.
    Study Type
    Observational
    Studied Population
    adults with moderate-to-severe atopic dermatitis who previously received dupilumab
    Results
    EASI-75 dupilumab non-responders 200mg: 80.0
    EASI-75 dupilumab non-responders 100mg: 67.7
    PP-NRS4 dupilumab non-responders 200mg: 77.3
    PP-NRS4 dupilumab non-responders 100mg: 37.8

    Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

    (Full Study)
    Summary:
    Abrocitinib (oral medication) worked better than dupilumab (injection) at reducing itch and eczema symptoms in adults with moderate-to-severe eczema, particularly in the early weeks of treatment.
    Study Type
    Randomized Controlled Trial
    Studied Population
    727 adults with moderate-to-severe atopic dermatitis who required systemic therapy or had inadequate response to topical medications
    Results
    PP-NRS4: 22.6% higher in abrocitinib group (p<0.0001)
    EASI-90: 14.1% higher in abrocitinib group (p<0.0001)
  • Treatment:
    Elidel (Pimecrolimus)
    Effectiveness:
    Who is this for?:
    If you need a long-term, steroid-sparing option and for treatment in sensitive areas
    If your child needs a long-term, steroid-sparing option and for treatment in sensitive areas
    Side Effects:
    Cost:
    -
    Delivery:
    Topical twice daily
    Studies
  • Treatment:
    Protopic (Tacrolimus)
    Effectiveness:
    Who is this for?:
    If you need a long-term, steroid-sparing option and for treatment in sensitive areas
    If your child needs a long-term, steroid-sparing option and for treatment in sensitive areas
    Side Effects:
    Cost:
    -
    Delivery:
    Topical 0.1% strength for adults, 0.03% for children twice daily initially, then twice weekly for maintenance
    Studies

    Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016

    (Full Study)
    Summary:
    These are clinical guidelines for treating eczema (atopic dermatitis) in Japan, recommending the use of topical steroids and tacrolimus ointment as main treatments, along with moisturizers and avoiding triggers.
    Study Type
    Review
    Studied Population
    patients with atopic dermatitis in Japan
    Results

    Atopic Dermatitis: Diagnosis and Treatment.

    (Full Study)
    Summary:
    Atopic dermatitis is a common chronic skin condition affecting 10% of people in their lifetime, with treatment options ranging from basic moisturizers to newer medications like dupilumab, though first-line treatment remains topical corticosteroids.
    Study Type
    Review
    Studied Population
    general population with atopic dermatitis
    Results

    ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

    (Full Study)
    Summary:
    This is a comprehensive position paper that provides guidelines for diagnosing and treating eczema in both adults and children, covering various treatment options from basic moisturizing to advanced medications like dupilumab, and emphasizing the importance of individualized care and education.
    Study Type
    Review
    Studied Population
    adults and children with atopic dermatitis
    Results

    Polymeric micelle nanocarriers for the cutaneous delivery of tacrolimus: a targeted approach for the treatment of psoriasis.

    (Full Study)
    Summary:
    A new way of delivering tacrolimus using tiny carriers called polymeric micelles was more effective at getting the medication into the skin compared to the existing ointment (Protopic), particularly targeting the areas affected by psoriasis without increasing absorption into the bloodstream.
    Study Type
    Observational
    Studied Population
    human skin samples (ex vivo study)
    Results
    Skin deposition difference: 3.19-fold higher deposition with micelle formulation

    Atopic keratoconjunctivitis

    (Full Study)
    Summary:
    A case study showed that using tacrolimus eye drops along with other treatments successfully improved severe eye inflammation and skin symptoms in a teenager with atopic dermatitis and eye complications within two months.
    Study Type
    Observational
    Studied Population
    1 15-year-old male with atopic keratoconjunctivitis and atopic dermatitis
    Results
    Symptom improvement: Complete resolution of symptoms after 2 months
    Quality of life: Significant improvement

    ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients

    (Full Study)
    Summary:
    This paper provides comprehensive guidelines for diagnosing and treating eczema in both adults and children, covering various treatment options from basic moisturizing to advanced medications, and emphasizing the importance of individualized treatment approaches.
    Study Type
    Review
    Studied Population
    adult and pediatric patients with atopic dermatitis
    Results

    Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study.

    (Full Study)
    Summary:
    Using tacrolimus ointment twice weekly helped prevent vitiligo patches from losing their recovered skin color compared to using a placebo, with only 9.7% of treated areas showing color loss versus 40% in the placebo group.
    Study Type
    Randomized Controlled Trial
    Studied Population
    35 adults with successfully repigmented vitiligo patches
    Results
    depigmentation_reduction: 21.6% lower depigmentation rate in treatment group

    Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I

    (Full Study)
    Summary:
    This is a European consensus guideline that outlines recommended treatments for eczema, focusing on basic skin care, topical treatments, light therapy, and itch management. The guidelines emphasize that treatment should be personalized since eczema affects everyone differently.
    Study Type
    Review
    Studied Population
    adults and children with atopic eczema
    Results

    A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation – JOELLE study)

    (Full Study)
    Summary:
    People using tacrolimus or pimecrolimus creams for eczema had a slightly higher risk of developing lymphoma compared to those using corticosteroid creams, but the actual number of cases was very small, suggesting minimal risk for individual patients.
    Study Type
    Observational
    Studied Population
    988527 children and adults using topical tacrolimus, pimecrolimus, or corticosteroids
    Results
    Lymphoma IRR tacrolimus vs TCS - children: 3.74
    Lymphoma IRR tacrolimus vs TCS - adults: 1.27
    CTCL IRR tacrolimus vs TCS - adults: 1.76
    CTCL IRR pimecrolimus vs TCS - adults: 1.31
    CTCL IRR TCS vs untreated - adults: 10.66

    European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

    (Full Study)
    Summary:
    This expert review provides guidance on which eczema treatments are safe to use during pregnancy planning, pregnancy, and breastfeeding. Topical treatments (like moisturizers, steroid creams) and light therapy are considered safe, while oral medications should be used cautiously and only specific ones are recommended.
    Study Type
    Review
    Studied Population
    adults with AD who are planning pregnancy, pregnant, or lactating
    Results
  • Treatment:
    Dupixent (Dupilumab)
    Effectiveness:
    Who is this for?:
    If topical treatments don't work for you
    If your child is 6+ months and topical treatments don't work for your child
    Side Effects:
    Cost:
    -
    Delivery:
    Injection None every 2 weeks
    Studies

    Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    (Full Study)
    Summary:
    Adding dupilumab to standard steroid cream treatment for 1 year significantly improved eczema symptoms compared to using steroid cream alone, with acceptable safety.
    Study Type
    Randomized Controlled Trial
    Studied Population
    740 adults with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids
    Results
    IGA 0/1: 27% more patients achieved clear/almost clear skin with dupilumab
    EASI-75: 46% more patients achieved significant improvement with dupilumab

    Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.

    (Full Study)
    Summary:
    Adding dupilumab injections to nasal steroid spray significantly reduced nasal polyps and improved sense of smell compared to using nasal steroid spray alone in patients with chronic sinusitis.
    Study Type
    Randomized Controlled Trial
    Studied Population
    51 adults with chronic sinusitis and nasal polyposis refractory to intranasal corticosteroids
    Results
    Nasal polyp score: -1.6
    Lund-Mackay CT score: -8.8
    SinoNasal Outcome Test: -18.1
    UPSIT score: 14.8

    Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

    (Full Study)
    Summary:
    Dupilumab significantly improved eczema symptoms compared to placebo, with the strongest improvements seen in higher doses given more frequently. The treatment was generally safe with similar side effects between treatment and placebo groups.
    Study Type
    Randomized Controlled Trial
    Studied Population
    379 adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments
    Results
    EASI % change: 50% greater improvement with dupilumab compared to placebo

    Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

    (Full Study)
    Summary:
    Dupilumab treatment improved eczema symptoms and skin health at the cellular level, while being well-tolerated by patients. The drug worked by reducing inflammation and improving skin barrier function over a 16-week period.
    Study Type
    Randomized Controlled Trial
    Studied Population
    54 patients with moderate-to-severe atopic dermatitis
    Results
    Transcriptome improvement: Significant improvement vs placebo (p<0.001)
    Epidermal thickness: Significant reduction vs placebo (week 4: p=0.001, week 16: p=0.0002)

    Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.

    (Full Study)
    Summary:
    Dupilumab treatment improved the molecular markers of atopic dermatitis in skin samples, showing that it effectively targets and reduces inflammation associated with the condition.
    Study Type
    Randomized Controlled Trial
    Studied Population
    patients with moderate-to-severe atopic dermatitis
    Results
    Gene expression improvement: Dose-dependent improvement with greater effects at 300mg dose
    TH2-associated chemokines: Significant decrease
    Hyperplasia markers: Significant decrease

    Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

    (Full Study)
    Summary:
    Dupilumab with topical steroids significantly improved eczema symptoms in adults who couldn't use or didn't respond to ciclosporin A, with about 60% of patients showing major improvement compared to 30% on placebo.
    Study Type
    Randomized Controlled Trial
    Studied Population
    318 adults with atopic dermatitis with inadequate response to/intolerance of ciclosporin A, or for whom ciclosporin A treatment was medically inadvisable
    Results
    EASI-75: 33% improvement over placebo

    Conjunctivitis in dupilumab clinical trials

    (Full Study)
    Summary:
    Patients taking dupilumab for atopic dermatitis had a higher chance of developing eye inflammation (conjunctivitis) compared to placebo, particularly if they had severe AD or previous eye problems, but this side effect was rare in patients taking the drug for other conditions.
    Study Type
    Review
    Studied Population
    5612 patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic oesophagitis
    Results

    Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

    (Full Study)
    Summary:
    Dupilumab significantly improved eczema symptoms, itching, and quality of life in adolescents with moderate-to-severe atopic dermatitis compared to placebo, with an acceptable safety profile.
    Study Type
    Randomized Controlled Trial
    Studied Population
    251 adolescents aged 12-17 years with moderate-to-severe atopic dermatitis inadequately controlled by topical medications
    Results
    EASI-75: 33.2
    IGA 0/1: 22.0
    Peak Pruritus NRS: -29.0

    Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.

    (Full Study)
    Summary:
    Dupilumab significantly improved eczema symptoms, itching, anxiety, depression, and quality of life compared to placebo in adults with moderate-to-severe eczema over 16 weeks of treatment.
    Study Type
    Randomized Controlled Trial
    Studied Population
    1379 adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatment
    Results
    IGA 0/1: 28% more patients achieved clear/almost clear skin with dupilumab vs placebo
    EASI-75: 28% more patients achieved 75% improvement with dupilumab vs placebo

    Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

    (Full Study)
    Summary:
    Dupilumab treatment showed rapid and significant improvement in eczema symptoms compared to placebo, with most patients showing at least 50% improvement in their condition. The medication was well-tolerated with mainly mild side effects like nasopharyngitis and headache.
    Study Type
    Randomized Controlled Trial
    Studied Population
    adults with moderate-to-severe atopic dermatitis
    Results
    EASI-50: 50 percentage point improvement over placebo
    IGA 0-1: 33 percentage point improvement over placebo
    Pruritus: 40.6 percentage point improvement over placebo
  • Treatment:
    Opzelura (Ruxolitinib)
    Effectiveness:
    Who is this for?:
    If you are looking for a short-term treatment with rapid relief of itch and inflammation, and other topical treatments have failed
    If your child is 12+ years and looking for a short-term treatment with rapid relief of itch and inflammation, and other topical treatments have failed
    Side Effects:
    Cost:
    -
    Delivery:
    Topical thin film to affected areas twice daily
    Studies
  • Treatment:
    Adbry (Tralokinumab)
    Effectiveness:
    Who is this for?:
    If topical prescription therapies don't work for you
    If you are 12+ years and topical prescription therapies don't work for you
    Side Effects:
    Cost:
    -
    Delivery:
    Injection 300mg every 2 weeks
    Studies
  • Treatment:
    Ebglyss (Lebrikizumab)
    Effectiveness:
    Who is this for?:
    If you need strong relief and topical treatments don't work for you
    If you are 12+, need strong relief and topical treatments don't work for you
    Side Effects:
    Cost:
    -
    Delivery:
    Injection every 2-4 weeks
    Studies

    Efficacy and safety of lebrikizumab (an anti‐IL‐13 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo‐controlled phase II trial (TREBLE)

    (Full Study)
    Summary:
    When combined with topical steroids, lebrikizumab taken every 4 weeks significantly improved eczema symptoms compared to placebo, with similar side effects between groups.
    Study Type
    Randomized Controlled Trial
    Studied Population
    209 adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids
    Results
    EASI-50: 20.1% improvement over placebo (p = 0.026)

    Therapeutic targeting of the IL-13 pathway in skin inflammation

    (Full Study)
    Summary:
    IL-13 plays a key role in atopic dermatitis, and drugs that block IL-13 (like tralokinumab and lebrikizumab) show promising results in treating moderate-to-severe eczema.
    Study Type
    Review
    Studied Population
    patients with moderate-to-severe atopic dermatitis
    Results

    Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.

    (Full Study)
    Summary:
    Lebrikizumab, given as an injection every 2 weeks, was significantly more effective than placebo in clearing skin and reducing itch in people with moderate-to-severe eczema over 16 weeks of treatment.
    Study Type
    Randomized Controlled Trial
    Studied Population
    851 adults (≥18 years) and adolescents (12-17 years, ≥40 kg) with moderate-to-severe atopic dermatitis
    Results
    IGA 0/1: 30.4% improvement over placebo in trial 1, 22.4% in trial 2
    EASI-75: 42.6% improvement over placebo in trial 1, 34% in trial 2

    Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis

    (Full Study)
    Summary:
    Lebrikizumab showed significant improvement in eczema symptoms compared to placebo over 16 weeks, with benefits seen as early as day 2 for itch relief. The medication was generally well-tolerated with few side effects.
    Study Type
    Randomized Controlled Trial
    Studied Population
    280 adults with moderate-to-severe atopic dermatitis
    Results

    Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.

    (Full Study)
    Summary:
    Lebrikizumab was effective at treating moderate-to-severe eczema over 52 weeks, with similar results whether given every 2 or 4 weeks after the initial 16-week treatment period. The medication was generally safe with most side effects being mild or moderate.
    Study Type
    Randomized Controlled Trial
    Studied Population
    adolescent and adult patients with moderate-to-severe atopic dermatitis
    Results

    New and Emerging Therapies for Pediatric Atopic Dermatitis

    (Full Study)
    Summary:
    This review discusses new treatments for eczema in children, including recently FDA-approved medications (crisaborole and dupilumab) and promising emerging therapies that target specific pathways in the immune system, potentially offering better effectiveness with fewer side effects than traditional treatments.
    Study Type
    Review
    Studied Population
    pediatric patients with atopic dermatitis
    Results

    Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro

    (Full Study)
    Summary:
    This laboratory study showed that IL-13 affects genes associated with skin barrier function and inflammation in atopic dermatitis, and that tralokinumab can block these effects.
    Study Type
    Observational
    Studied Population
    human skin cells in laboratory
    Results

    Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis

    (Full Study)
    Summary:
    Several new biologic medications (lebrikizumab, tralokinumab, fezakinumab, nemolizumab, and GBR 830) showed promising results in treating moderate-to-severe atopic dermatitis in adults, while two others (tezepelumab and etokimab) did not show significant improvements.
    Study Type
    Review
    Studied Population
    adults with moderate-to-severe AD
    Results

    Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information

    (Full Study)
    Summary:
    Using computer analysis of genetic data, researchers identified 53 existing drugs that might be useful for treating atopic dermatitis, including some that are already being tested or used for this condition.
    Study Type
    Review
    Studied Population
    genomic data analysis
    Results
  • Treatment:
    Eucrisa (Crisaborole)
    Effectiveness:
    Who is this for?:
    If you need a non-steroid topical treatment, especially in sensitive areas
    If your child needs a non-steroid topical treatment, especially in sensitive areas
    Side Effects:
    Cost:
    -
    Delivery:
    Topical twice daily
    Studies

    Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

    (Full Study)
    Summary:
    Crisaborole ointment was more effective than placebo at treating eczema symptoms and was found to be safe with mostly mild side effects when applied twice daily for 28 days.
    Study Type
    Randomized Controlled Trial
    Studied Population
    children and adults with mild to moderate atopic dermatitis
    Results
    ISGA success: Significantly higher success rates in crisaborole group (p=0.038 in AD-301, p<0.001 in AD-302)
    Time to improvement: Crisaborole achieved success faster than vehicle (p≤0.001)

    Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open‐Label Phase 2a Study

    (Full Study)
    Summary:
    Crisaborole 2% ointment applied twice daily showed limited absorption into the body and was generally safe when used by teenagers with eczema, with some patients showing improvement in their condition after 29 days.
    Study Type
    Observational
    Studied Population
    23 adolescents aged 12-17 years with mild to moderate atopic dermatitis affecting 10-35% body surface area
    Results
    BSA reduction: Decreased from 17.6% to 8.2%

    Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)

    (Full Study)
    Summary:
    Crisaborole ointment 2% was found to be safe and effective when used twice daily in infants with mild-to-moderate eczema, with most side effects being mild and occurring at the application site.
    Study Type
    Observational
    Studied Population
    137 infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis
    Results
    ISGA clear/almost clear: 30.2% achieved clear/almost clear with ≥2-grade improvement
    EASI score: 57.5% improvement
    POEM score: 8.5 point reduction

    Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.

    (Full Study)
    Summary:
    Crisaborole 2% ointment was more effective than placebo in treating eczema lesions, with 68% of patients showing better improvement in the treated area compared to the untreated area. The medication was generally safe with mostly mild side effects.
    Study Type
    Randomized Controlled Trial
    Studied Population
    25 adults with mild to moderate atopic dermatitis
    Results
    ADSI improvement: 68% of patients had greater improvement in treated lesion vs vehicle-treated lesion

    A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.

    (Full Study)
    Summary:
    Crisaborole ointment applied twice daily at 2% strength was effective in treating mild to moderate eczema in teenagers, improving symptoms by 71% after 29 days with only mild side effects at the application site.
    Study Type
    Randomized Controlled Trial
    Studied Population
    86 adolescents 12-17 years with mild to moderate atopic dermatitis
    Results

    Application of Topical Phosphodiesterase 4 Inhibitors in Mild to Moderate Atopic Dermatitis: A Systematic Review and Meta-analysis

    (Full Study)
    Summary:
    Topical PDE4 inhibitors (particularly crisaborole and AN2898) were found to be safe and effective treatments for mild to moderate eczema, showing significant improvement in skin symptoms compared to vehicle (placebo) treatment.
    Study Type
    Review
    Studied Population
    1869 patients with mild to moderate atopic dermatitis
    Results
    Target lesion score: SMD -0.40 (95% CI, -0.61 to -0.18, P < .001)
    Clear/almost clear skin: 50% higher response rate compared to control (RR 1.50; 95% CI, 1.33-1.70; P < .001)

    Atopic Dermatitis: Diagnosis and Treatment.

    (Full Study)
    Summary:
    Atopic dermatitis is a common chronic skin condition affecting 10% of people in their lifetime, characterized by itchy skin lesions. Treatment typically includes moisturizers, gentle cleansers, and topical corticosteroids as first-line therapy, with newer treatments available for more severe cases.
    Study Type
    Review
    Studied Population
    general population with atopic dermatitis
    Results

    Long‐term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis

    (Full Study)
    Summary:
    Crisaborole ointment showed good safety when used for up to 48 weeks, with most side effects being mild and not related to the treatment.
    Study Type
    Observational
    Studied Population
    517 children and adults (≥2 years) with mild to moderate atopic dermatitis
    Results

    Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study

    (Full Study)
    Summary:
    Crisaborole 2% ointment applied twice daily was found to be safe with limited absorption into the body, and helped improve eczema symptoms in children aged 2-17 years when applied for 28 days.
    Study Type
    Observational
    Studied Population
    34 children ages 2-17 years with mild to moderate AD involving 25% or more treatable body surface area
    Results
    ISGA change from baseline: -1.5
  • Treatment:
    Zoryve (Roflumilast)
    Effectiveness:
    Who is this for?:
    If you are looking for a non-steroidal cream with good tolerability
    If your child is 6+ years and looking for a non-steroidal cream with good tolerability
    Side Effects:
    Cost:
    -
    Delivery:
    Topical once daily
    Studies
Off-label
  • Treatment:
    CellCept (Mycophenolate mofetil)
    Effectiveness:
    Who is this for?:
    If you have widespread flareups and topicals don't work for you
    None
    Side Effects:
    Cost:
    -
    Delivery:
    Oral daily
    Studies
  • Treatment:
    Gengraf, Neoral (Cyclosporine)
    Effectiveness:
    Who is this for?:
    If other treatments don't work for you and you are looking for relief within 1-2 weeks
    None
    Side Effects:
    Cost:
    -
    Delivery:
    Oral daily
    Studies
  • Treatment:
    Otrexup, Rasuvo, Trexall, Xatmep, … (Methotrexate)
    Effectiveness:
    Who is this for?:
    If you have severe eczema that affects a large part of your body and doesn't respond well to steroids
    None
    Side Effects:
    Cost:
    -
    Delivery:
    ['oral', 'injection'] daily
    Studies
Supplement
  • Treatment:
    Vitamin D3 (Cholecalciferol)
    Effectiveness:
    Who is this for?:
    If your symptoms get worse during winter or you have confirmed low Vitamin D levels
    If your child's symptoms get worse during winter or your child has confirmed low Vitamin D levels
    Side Effects:
    Cost:
    -
    Delivery:
    Oral 1000-4000 IU daily
    Studies
  • Treatment:
    Probiotics (Lactobacillus, Bifidobacterium)
    Effectiveness:
    Who is this for?:
    As a complementary treatment alongside standard therapies
    As a complementary treatment for children with moderate atopic dermatitis
    Side Effects:
    Cost:
    -
    Delivery:
    Oral daily
    Studies
  • Treatment:
    Vitamin B12 (Cobalamin)
    Effectiveness:
    Who is this for?:
    As an add-on alongside other therapies
    As an add-on alongside other therapies
    Side Effects:
    Cost:
    -
    Delivery:
    Oral daily
    Studies
  • Treatment:
    Omega-3 (Polyunsaturated fatty acid)
    Effectiveness:
    Who is this for?:
    As a supplement to other treatments, especially during pregnancy and breastfeeding
    As a supplement to other treatments
    Side Effects:
    Cost:
    -
    Delivery:
    Oral None daily
    Studies
Other
  • Treatment:
    Coconut Oil (Virgin Coconut Oil)
    Effectiveness:
    Who is this for?:
    If you are looking for a gentle and natural moisturizer that may help reduce inflammation and bacterial colonization
    If you are looking for a gentle and natural moisturizer for your child that may help reduce inflammation and bacterial colonization
    Side Effects:
    Cost:
    -
    Delivery:
    Topical as needed daily
    Studies
  • Treatment:
    Oils (Other than coconut)
    Effectiveness:
    Who is this for?:
    If you are looking for a gentle and natural moisturizer that may help reduce inflammation and bacterial colonization
    If you are looking for a gentle and natural moisturizer that may help reduce inflammation and bacterial colonization
    Side Effects:
    Cost:
    -
    Delivery:
    Topical daily
    Studies